Jump to Main Contents
研究所ロゴ

Home > Organization > Divisions and Independent Research Units > Group for Cancer Development and Progression > Division of Cellular Signaling > Research Papers

Research Papers

2017

Division of Cellular Signaling

  1. Soh SX, Siddiqui FJ, Allen JC, Kim GW, Lee JC, Yatabe Y, Soda M, Mano H, Soo RA, Chin TM, Ebi H, Yano S, Matsuo K, Niu X, Lu S, Isobe K, Lee JH, Yang JC, Zhao M, Zhou C, Lee JK, Lee SH, Lee JY, Ahn MJ, Tan TJ, Tan DS, Tan EH, Ong ST, Lim WT.“A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer” Oncotarget 2017. [PubMed ]
  2. Nakamura T, Yamashita S, Fukumura K, Nakabayashi J, Tanaka K, Tamura K, Tateishi K, Kinoshita M, Fukushima S, Takami H, Fukuoka K, Yamazaki K, Matsushita Y, Ohno M, Miyakita Y, Shibui S, Kubo A, Shuto T, Kocialkowski S, Yamanaka S, Mukasa A, Sasayama T, Mishima K, Maehara T, Kawahara N, Nagane M, Narita Y, Mano H, Ushijima T & Ichimura K.“Genome-wide DNA methylation profiling identifies primary central nervous system lymphoma as a distinct entity different from systemic diffuse large B-cell lymphoma” Acta Neuropathol 133, 321-4, 2017. [PubMed ]
  3. Kawazu M, Kojima S, Ueno T, Totoki Y, Nakamura H, Kunita A, Qu W, Yoshimura J, Soda M, Yasuda T, Hama N, Saito-Adachi M, Sato K, Kohsaka S, Sai E, Ikemura M, Yamamoto S, Ogawa T, Fukayama M, Tada K, Seto Y, Morishita S, Hazama S, Shibata T, Yamashita Y and Mano H: “Integrative analysis of genomic alterations in triple-negative breast cancer in association with homologous recombination deficiency” PLoS Genet 13, e1006853, 2017 [PubMed ].

Lab of Collaborative Research(Shiotani Group)

  1. Asano N, Yoshida A, Mitani S, Kobayashi E, Shiotani B, Komiyama M, Fujimoto H, Chuman H, Morioka H, Matsumoto M, Nakamura M, Kubo T, Kato M, Kohno T, Kawai A, Kondo T, Ichikawa H. Frequent amplification of receptor tyrosine kinase genes in welldifferentiated/ dedifferentiated liposarcoma. Oncotarget. 8 : 12941-12952 doi: 10.18632/oncotarget.14652; 2017 [PubMed ]

Lab of Collaborative Research(Masuda Group)

  1. Yamada T, Masuda M. Emergence of TNIK inhibitors in cancer therapeutics. Cancer Sci. 2017 May; 108(5):818-823. [PubMed ]
  2. Hirata Y, Kobayashi T, Nishiumi S, Yamanaka K, Nakagawa T, Fujigaki S, Iemoto T, Kobayashi M, Okusaka T, Nakamori S, Shimahara M, Ueno T, Tsuchida A, Sata N, Ioka T, Yasunami Y, Kosuge T, Kaneda T, Kato T, Yagihara K, Fujita S, Yamada T, Honda K, Azuma T, Yoshida M. Identification of highly sensitive biomarkers that can aid the early detection of pancreatic cancer using GC/MS/MS-based targeted metabolomics. Clinica Chimica Acta. 2017 May; 468:98-104. [PubMed ]
  3. Masuda M, Yamada T. The emergence of TNIK as a therapeutic target for colorectal cancer. Expert Opin Ther Targets. 2017 Apr; 21(4):353-355. [PubMed ]
  4. Hashimoto T, Yamashita S, Yoshida H, Taniguchi H, Ushijima T, Yamada T, Saito Y, Ochiai A, Sekine S, Hiraoka N. WNT Pathway Gene Mutations are Associated with the Presence of Dysplasia in Colorectal Sessile Serrated Adenoma/Polyps. Am J Surg Pathol. 2017 Jun 13. [PubMed ]
  5. Shoji H, Tada K, Kitano S, Nishimura T, Shimada Y, Nagashima K, Aoki K, Hiraoka N, Honma Y, Iwasa S, Takashima A, Kato K, Boku N, Honda K, Yamada T, Heike Y, Hamaguchi T. The peripheral immune status of granulocytic myeloid-derived suppressor cells correlates the survival in advanced gastric cancer patients receiving cisplatin-based chemotherapy. Oncotarget. 2017 May 30. [PubMed]
  6. Masuda M, Yamada T. Signaling pathway profiling using reverse-phase protein array and its clinical applications. Expert Rev Proteomics. 2017 Jun, [PubMed]

2016

Division of Cellular Signaling

  1. Yasuda T, Tsuzuki S, Kawazu M, Hayakawa F, Kojima S, Ueno T, Imoto N, Kohsaka S, Kunita A, Doi K, Sakura T, Yujiri T, Kondo E, Fujimaki K, Ueda Y, Aoyama Y, Ohtake S, Takita J, Sai E, Taniwaki M, Kurokawa M, Morishita S, Fukayama M, Kiyoi H, Miyazaki Y, Naoe T & Mano H. “Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults” Nat Genet 48, 569-574, 2016. [PubMed ]
  2. Ando M, Kawazu M, Ueno T, Koinuma D, Ando K, Koya J, Kataoka K, Yasuda T, Yamaguchi H, Fukumura K, Yamato A, Soda M, Sai E, Yamashita Y, Asakage T, Miyazaki Y, Kurokawa M, Miyazono K, Nimer SD, Yamasoba T & Mano H. “Mutational landscape and antiproliferative functions of ELF transcription factors in human cancer” Cancer Res 76, 1814-1824, 2016. [PubMed ]
  3. Fukumura K, Kawazu M, Kojima S, Ueno T, Sai E, Soda M, Ueda H, Yasuda T, Yamaguchi H, Lee J, Shishido-Hara Y, Sasaki A, Shirahata M, Mishima K, Ichimura K, Mukasa A, Narita Y, Saito N, Aburatani H, Nishikawa R, Nagane M & Mano H. “Genomic characterization of primary central nervous system lymphoma” Acta Neuropathol 131, 865-875, 2016. [PubMed ]
  4. Katsura A, Suzuki HI, Ueno T, Mihira H, Yamazaki T, Yasuda T, Watabe T, Mano H, Yamada Y & Miyazono K. “MicroRNA-31 is a positive modulator of endothelial-mesenchymal transition and associated secretory phenotype induced by TGF-beta” Genes Cells 21, 99-116, 2016. [PubMed ]

Lab of Collaborative Research(Masutani Group)

  1. Hirai T, Saito S, Fujimori H, Matsushita K, Nishio T, Okayasu R, Masutani M. Radiosensitization by PARP inhibition to proton beam irradiation in cancer cells. Biochemical and Biophysical Research Communication 478(1):234-40, 2016 [PubMed ]
  2. Sasaki Y, Hozumi M, Fujimori H, Murakami Y, Koizumi F, Inoue K, Masutani M, PARG inhibitors and functional PARG inhibition models. Current Protein and Peptide Science 17: 641-653, 2016 [PubMed ]
  3. Wang J, Ding Q, Fujimori H, Motegi A, Miki Y, Masutani M. Loss of CtIP disturbs homologous recombination repair and sensitizes breast cancer cells to PARP inhibitors. Oncotarget 7(7):7701-14. 2016 [PubMed ]
  4. Osada T, Tadashige Nozaki T, Masutani M Parp1 deficiency confers defects in chromatin surveillance and remodeling during reprogramming by nuclear transfer. Current Protein and Peptide Science 17: 693-704, 2016 [PubMed ]
  5. Yasukawa M, Fujihara H, Fujimori H, Kawaguchi K, Yamada H, Nakayama R, Yamamoto N, Kishi Y, Hamada Y, Masutani M. Synergetic effects of PARP inhibitor AZD2281 and cisplatin in oral squamous cell carcinoma in vitro and in vivo. Int J Mol Sci. 17(3):272, 2016 [PubMed ]

Lab of Collaborative Research(Shiotani Group)

Lab of Collaborative Research(Masuda Group)

  1. Shiba S, Morizane C, Hiraoka N, Sasaki M, Koga F, Sakamoto Y, Kondo S, Ueno H, Ikeda M, Yamada T, Shimada K, Kosuge T, Okusaka T.Pancreatic neuroendocrine tumors: A single-center 20-year experience with 100 patients. Pancreatology. 2016 Jan-Feb;16(1):99-105. [PubMed ]
  2. Sawa M, Masuda M, Yamada T. Targeting the Wnt signaling pathway in colorectal cancer. Expert Opin Ther Targets. 2016 Apr;20(4):419-29. [PubMed ]
  3. Masuda M, Uno Y, Ohbayashi N, Ohata H, Mimata A, Kukimoto-Niino M, Moriyama H, Kashimoto S, Inoue T, Goto N, Okamoto K, Shirouzu M, Sawa M, Yamada T. TNIK Inhibition Abrogates Colorectal Cancer Stemness. Nature Communications. 2016 Aug 26;7:12586. [PubMed ]
  4. Miura N, Kamita M, Kakuya T, Fujiwara Y, Tsuta K, Shiraishi H, Takeshita F, Ochiya T, Shoji H, Huang W, Ohe Y, Yamada T, Honda K. Efficacy of adjuvant chemotherapy for non-small cell lung cancer assessed by metastatic potential associated with ACTN4. Oncotarget. 2016 May 31;7(22):33165-78. [PubMed ]
  5. Takahashi N, Iwasa S, Fukahori M, Sudo K, Sasaki Y, Shoji H, Honma Y, Okita NT, Takashima A, Hamaguchi T, Boku N, Shimada Y, Honda K, Yamada T, Yamada Y. A phase I study of the combination of panitumumab and bevacizumab in KRAS wild-type colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, irinotecan and bevacizumab. Cancer Chemother Pharmacol. 2016 Sep;78(3):567-75. [PubMed ]
  6. Yoneyama T, Ohtsuki S, Honda K, Kobayashi M, Iwasaki M, Uchida Y, Okusaka T, Nakamori S, Shimahara M, Ueno T, Tsuchida A, Sata N, Ioka T, Yasunami Y, Kosuge T, Kaneda T, Kato T, Yagihara K, Fujita S, Huang W, Yamada T, Tachikawa M, Terasaki T. Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics. PLoS One. 2016 Aug 31;11(8):e0161009 [PubMed ]

2015

Division of Cellular Signaling

  1. Yamaguchi H, Kawazu M, Yasuda T, Soda M, Ueno T, Kojima S, Yashiro M, Yoshino I, Ishikawa Y, Sai E & Mano H. “Transforming somatic mutations of mammalian target of rapamycin kinase in human cancer” Cancer Sci 106, 1687-1692, 2015. [PubMed]
  2. Yamato A, Soda M, Ueno T, Kojima S, Sonehara K, Kawazu M, Sai E, Yamashita Y, Nagase T & Mano H. “Oncogenic activity of BIRC2 and BIRC3 mutants independent of nuclear factor-kappaB-activating potential” Cancer Sci 106, 1137-1142, 2015. [PubMed]
  3. Ikeda K, Horie-Inoue K, Ueno T, Suzuki T, Sato W, Shigekawa T, Osaki A, Saeki T, Berezikov E, Mano H & Inoue S. “miR-378a-3p modulates tamoxifen sensitivity in breast cancer MCF-7 cells through targeting GOLT1A” Sci Rep 5, 13170, 2015. [PubMed]
  4. Mano H. “Second-generation ALK inhibitors” Clin Adv Hematol Oncol 13, 416-417, 2015. [PubMed]
  5. Suzuki HI, Katsura A, Yasuda T, Ueno T, Mano H, Sugimoto K & Miyazono K. “Small-RNA asymmetry is directly driven by mammalian Argonautes” Nat Struct Mol Biol 22, 512-521, 2015. [PubMed]
  6. Hashizume O, Ohnishi S, Mito T, Shimizu A, Iashikawa K, Nakada K, Soda M, Mano H, Togayachi S, Miyoshi H, Okita K & Hayashi J. “Epigenetic regulation of the nuclear-coded GCAT and SHMT2 genes confers human age-associated mitochondrial respiration defects” Sci Rep 5, 10434, 2015. [PubMed]
  7. Mano H. “The EML4-ALK oncogene: targeting an essential growth driver in human cancer” Proc Jpn Acad Ser B Phys Biol Sci 91, 193-201, 2015. [PubMed]

Lab of Collaborative Research(Shiotani Group)

  1. Fujimori H, Sato A, Kikuhara S, Wang J, Hirai T, Sasaki Y, Murakami Y, Okayasu R, Masutani M: A comprehensive analysis of radiosensitization targets; functional inhibition of DNA methyltransferase 3B radiosensitizes by disrupting DNA damage regulation. Sci Rep 5:18231, 2015 [PubMed ]
  2. Sato A, Itoh T, Imamichi S, Kikuhara S, Fujimori H, Hirai T, Saito S, Sakurai Y, Tanaka H, Nakamura H, Suzuki M, Murakami Y, Baiseitov D, Berikkhanova K, Zhumadilov Z, Imahori Y, Itami J, Ono K, Masunaga S, Masutani M: Proteomic analysis of cellular response induced by boron neutron capture reaction in human squamous cell carcinoma SAS cells. Appl Rad Isot 106:213-219, 2015 [PubMed ]

Lab of Collaborative Research(Shiotani Group)

  1. Matsunuma R, Niida H, Ohhata T, Kitagawa K, Sakai S, Uchida C, Shiotani B, Matsumoto M, Nakayama KI, Ogura H, Shiiya N, Kitagawa M.UV Damage-Induced Phosphorylation of HBO1 Triggers CRL4DDB2-Mediated Degradation To Regulate Cell Proliferation. Mol Cell Biol. 36: 394-406; 2015 [PubMed ]

Lab of Collaborative Research(Masuda Group)

  1. Watanabe T, Ueno H, Watabe Y, Hiraoka N, Morizane C, Itami J, Okusaka T, Miura N, Kakizaki T, Kakuya T, Kamita M, Tsuchida A, Wilber H, Yamada T, Honda K. ACTN4 copy number as a predictive biomarker for chemoradiotherapy of locally advanced pancreatic cancer. Br J Cancer.112:704-13, 2015, [PubMed ]
  2. Kamita M, Mori T, Sakai Y, Ito S, Gomi M, Miyamoto Y, Harada A, Niida S, Yamada T, Watanabe K, Ono M. Proteomic analysis of ligamentum flavum from patients with lumbar spinal stenosis. Proteomics. 15:1622-30, 2015, [PubMed ]
  3. Okamoto N, Suzuki H, Kawahara K, Honda K, Miura N, Hirashima T, Tamiya M, Morishita N, Shiroyama T, Tanaka A, Tani E, Hamaguchi M, Kitani M, Yamada T, Kawase I. The alternatively spliced actinin-4 variant as a prognostic marker for metastasis in small-cell lung cancer. Anticancer Res. 35:1663-7, 2015, [PubMed ]
  4. Miyanaga A, Masuda M, Tsuta K, Kawasaki K, Nakamura Y, Sakuma T, Asamura H, Gemma A, Yamada T. Hippo Pathway Gene Mutations in Malignant Mesothelioma Revealed by RNA and Targeted Exon Sequencing. J Thoracic Oncol. 10:844-51, 2015, [PubMed ]
  5. Fukumoto M, Kurisu S, Yamada T, Takenawa T. α-Actinin 4 Enhances Cell Invasion by Suppressing Maturation of Focal Adhesions. PLos One. 10:e0120616, 2015, [PubMed ]
  6. Arai E, Gotoh M, Tian Y, Sakamoto H, Ono M, Matsuda A, Takahashi Y, Miyata S, Totsuka H, Chiku S, Komiyama M, Fujimoto H, Matsumoto K, Yamada T, Yoshida T, Kanai Y. Alterations of the spindle checkpoint pathway in clinicopathologically aggressive CpG island methylator phenotype clear cell renal cell carcinomas. Int J Cancer. 137:2589-606, 2015, [PubMed ]
  7. Honda K, Kobayashi M, Okusaka T, Rinaudo JA, Huang Y, Marsh T, Sasajima Y, Nakamori S, Sanada M, Shimahara M, Ueno T, Tsuchida A, Sata N, Ioka T, Yasunami Y, Kosuge T, Miura N, Kamita M, Sakamoto T, Shouji H, Jung G, Srivastava S, Yamada T. Plasma biomarker for detection of early stage pancreatic cancer and risk factors for pancreatic malignancy using antibodies for apolipoprotein-AII isoforms. Sci. Rep. 15921, 2015, [PubMed ]
  8. Masuda M, Sawa M, Yamada T. Therapeutic targets in the Wnt signaling pathway: feasibility of targeting TNIK in colorectal cancer. Pharmacology & Therapeutics. 156:1-9, 2015, [PubMed ]